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Abstract: 
Introduction: 
135
La has favorable nuclear and chemical properties for Auger-based targeted internal 
radiotherapy. Here we present detailed investigations of the production, emissions, and dosimetry related 
to 
135
La therapy. 
Methods and Results: 
135
La was produced by 16.5 MeV proton irradiation of metallic 
nat
Ba on a medical 
cyclotron, and was isolated and purified by trap-and-release on weak cation-exchange resin. The average 
production rate was 407 ± 19 MBq/µA (saturation activity), and the radionuclidic purity was 98% at 20 h 
post irradiation. Chemical separation recovered > 98 % of the 
135
La with an effective molar activity of 70 
± 20 GBq/µmol. To better assess cellular and organ dosimetry of this nuclide, we have calculated the X-
ray and Auger emission spectra using a Monte Carlo model accounting for effects of multiple vacancies 
during the Auger cascade. The generated Auger spectrum was used to calculate cellular S-factors.  
Conclusion: 
135
La was produced with high specific activity, reactivity, radionuclidic purity, and yield.  
The emission spectrum and the dosimetry are favorable for internal radionuclide therapy. 
Keywords: lanthanum-135, La-135, radiolanthanide, auger therapy, targeted radionuclide therapy, 
radionuclide production 
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Introduction:  1 
The development of targeted internal radiotherapy for cancer and patient specific treatment requires 2 
radionuclides with suitable half-lives, chemical properties and emissions. Several nuclides are already in 3 
clinical use, notably the beta emitters 
177
Lu and 
90
Y [1,2]. In addition, preclinical studies with other 4 
lanthanides, especially the terbium isotopes 
149, 151, 155, 161
Tb show promise, providing a matched set of 5 
isotopes with diagnostic positrons and therapeutic alpha- and beta-particles, as well as Auger electrons 6 
[3–6]. The radioactive isotopes of lanthanum are chemically similar to the other lanthanides, and one in 7 
particular, 
135
La has potential as a therapeutic Auger electron emitter.    8 
 9 
Auger electron emitters are particularly interesting because they have the capability to deliver radiation 10 
dose to individual targeted cells while sparing surrounding tissues. This is in contrast to more commonly-11 
used therapeutic nuclides, like 
177
Lu and 
90
Y, which have beta emissions that traverse many cell lengths, 12 
with dispersed energy deposition. The very low energy and multiplicity of Auger electrons may prove 13 
useful in targeted therapy, especially in the treatment of diffuse and disseminated disease, where other 14 
nuclear emissions do not allow adequate dose to the targeted cell due to excessive particle range. Further, 15 
there is mounting evidence that the relative biological effectiveness (RBE) of multiple low energy 16 
electrons (<10 keV) significantly exceeds that of photons and higher energy beta particles [7]. In some 17 
cases the biological effect of absorbed dose from Auger electrons is 2-10 times higher than X-rays of the 18 
same energy, meaning that these emissions are more potent in introducing radiation damage to living cells 19 
[8–10]. Therefore, coupling Auger emitting radionuclides like 
135
La with highly specific targeting vectors, 20 
particularly cell-nucleus targeting moieties, has potential as a powerful therapeutic tool. 21 
  22 
135
La decays by electron capture (EC), primarily ( >98%) to the ground state of stable 
135
Ba, with a half-23 
life of 18.9 hour [11] (Figure 1). Following the decay Auger electrons are emitted which are potentially 24 
useful for internal radiotherapy. Throughout this paper we use the term “Auger electrons” as designation 25 
for all Auger cascade electrons, including the Coster-Kronig and Super-Coster-Kronig electrons. X-rays 26 
accompany the Auger cascade with a spectrum sufficient for Single Photon Emission Computed 27 
Tomography (SPECT) imaging capabilities. In small-animal studies this allows for concurrent SPECT 28 
imaging, facilitating dosimetry calculations in small-animal models [12]. In the projected future human 29 
use of therapeutic doses, the activity could be high enough to allow whole-body SPECT based on the low 30 
abundance (1.5% branch) 480.5 keV gamma emissions. 31 
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   32 
Figure 1 Simplified  decay scheme of 
135
La[11,13].   33 
 34 
When considering employing 
135
La as a radiotherapeutic nuclide, it is necessary to make detailed dose 35 
calculations. This is important not only on the organ level, but also on the cellular level, due to the highly 36 
localized dose deposition from emitted Auger electrons. In order to get a realistic dose estimate the entire 37 
emission spectrum needs to be well understood. The conventionally-used databases (like NuDat 2 [14]) 38 
only give a condensed version of the Auger cascade emissions, without addressing the many electrons 39 
below 3 keV. Lee et al. recently developed an Auger-cascade model, BrIccEmis, based on a Monte Carlo 40 
technique for determining X-ray and Auger emission spectra [15,16]. For the present work, the model was 41 
used to obtain detailed radiation spectra from 
135
La, especially for very low-energy Auger electrons and 42 
X-rays. Prescher et al. [17], and Tárkányi et al. [18] determined the production cross-sections for 
135
La 43 
during proton irradiation of 
nat
Ba at energies ranging from 12-70 MeV. Evident in their data is the fact 44 
that 
135
La is the primary radionuclide with half-life longer than a few minutes produced in the proton-45 
induced reactions on natural barium at energies available on most medical cyclotrons.   46 
 47 
In this work, we detail the properties of 
135
La as a radiotherapeutic nuclide. The practical considerations 48 
of production, purification, and radiolabeling are experimentally determined and optimized for the 49 
chelator DTPA (diethyeneltriaminepentacetic acid). Additionally, reevaluations of the Auger and X-ray 50 
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emission spectra are presented along with a calculation of the cellular S-factors and a dosimetry 51 
comparison to the commonly used radiotherapeutic isotopes 
177
Lu and 
90
Y.    52 
 53 
Materials and Methods: 54 
General 55 
All reagents were obtained from Sigma Aldrich and used without further purification unless otherwise 56 
noted. All water was 18 MΩ MilliQ-grade (Sartorious). Hydrochloric acid (HCl) solutions were diluted 57 
from 37% aq. HCl (Fluka TraceSelect) with water. pH was determined by pH paper (PEHANON 1-12 58 
and 4-9). Gamma spectroscopy was performed on a Princeton Gammatech LGC 5 germanium detector, 59 
calibrated using certified 
133
Ba and 
152
Eu sources.  60 
 61 
Cyclotron Production of 
135
La from 
nat
Ba 62 
Chunks of dendritically distilled metallic barium (99.99% trace metal grade) totaling 314-550 mg were 63 
pressed with a hydraulic press (20 kN/cm
2
) into a 9 mm diameter x 3 mm deep divot in a 28 mm diameter 64 
x 5 mm thick silver disc. The barium was immediately covered with either 100 µm aluminum or 25 µm 65 
niobium foil to reduce the exposure to atmospheric oxygen, and placed into a target holder supplying 66 
direct water cooling to the backside of the silver. A rough schematic of the target and target holder can be 67 
seen in a paper by Severin et al. [19]. The target holder was mounted onto a PETtrace cyclotron (PT800 68 
General Electric) and irradiated at 90° (normal) incidence with 16.5 MeV protons at 15 µA for 235-280 69 
min. Owing to the co-production of short-lived 
134
La (t½ = 6.5 min) and 
136
La (t½ = 9.9 min), and slightly 70 
longer-lived 
132
La (t½ = 4.5 h) and 
133
La (t½ = 3.9 h), the targets were allowed to decay for 12-24 hours 71 
before further handling.  72 
 73 
In order to determine the production rates of 
135
La and the other longer-lived co-produced radioisotopes 74 
(
132
La, 
133
La and 
135m
Ba), a single thick target of Ba totaling 472 mg was irradiated at 30 µA for 227 75 
minutes. This target was dissolved 19.8 hours post irradiation in 5 mL 1.2 M HCl, transferred to a plastic 76 
vial, and the radionuclidic contents were quantified by gamma spectroscopy. 77 
 78 
Purification of 
135
La  79 
The cover foil was removed and the silver disc mounted in a dissolution chamber allowing the barium to 80 
be dissolved with 2 mL 4 M aq. HCl. After complete dissolution of the 
nat
Ba, the solution was transferred 81 
to a vial along with 1-2 mL of water to rinse. Adding the water also served to dissolve any additional 82 
white precipitate present after oxidation of Ba in HCl/water. Therefore, concentrated HCl was added to 83 
the dissolved target to bring the HCl concentration to 1 M acidity in a final volume of 4 mL. The solution 84 
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was then heated at 70 °C for at least 30 min. The pH was adjusted to ~6 with 5 mL HEPES buffer (4-(2-85 
hydroxyethyl)-1-piperazineethanesulfonic acid) (1 M, pH = 7.3, HCl/NaOH adj.) and NaOH (1 M) and 86 
passed over 100 mg CM resin (Waters Accell Plus CM weak cation exchange resin) packed in a 4 mm 87 
inner diameter column with polyethylene frits in order to trap the 
135
La. The CM resin had been prepped 88 
by sequential washing with 5 mL acetonitrile, 5 mL 0.1 M HCl, 10 mL water, and 3 mL 1 M HEPES pH 89 
7.3.  After trapping the 
135
La, the resin was washed with 25 mL of water.  Finally, the column was eluted 90 
with 1 mL 0.1 M HCl to obtain the purified 
135
La.  91 
 92 
Specific activity measurements 93 
Analysis by ICP-OES (inductively coupled plasma optical emission spectroscopy) was performed on the 94 
samples to determine the non-radioactive, competitive metal content. The trace metals were quantified 95 
using a ThermoScientific iCAP 6000 Series instrument with iTeva software. The spectrometer was 96 
calibrated against standard solutions containing La, Ba, Cr, Mn, Co, Fe, Zn and Cu, which were prepared 97 
by dissolution and dilution of chloride salts of the tested metals in 0.3 M HCl. Samples for analysis were 98 
likewise diluted in 0.3 M HCl. 99 
 100 
The effective molar activity was determined experimentally via titration of the purified 
135
La with DTPA. 101 
DTPA solutions were prepared in water by serial dilution to make concentrations spanning 8-5000 nM. 102 
From these, 400 µL of each concentration was moved to an Eppendorf tube and buffered by addition of 103 
100 µL of HEPES (1 M, pH = 7.4). The molar amount of DTPA used in the titration ranged 3.2-2000 104 
pmol in 5 steps. To each of these Eppendorf tubes, 10 µL of 0.1 M HCl containing 3.5-4.5 MBq of 
135
La 105 
was added bringing the final pH to ~7 measured on pH paper. The titrations were performed in duplicate 106 
for each separation (n = 3) with one reacting at room temperature and the other reacting at 70 °C. After 30 107 
minutes, the reactions were analyzed by thin-layer chromatography (TLC) performed on aluminum-108 
backed silica (Merck TLC silica gel 60 F254), eluted with 5% (w/v) ammonium acetate in a 1:1 mixture 109 
of methanol and water. In this system La-DTPA moves with the eluent, while un-chelated La
3+
 remained 110 
at the origin. TLC plates were analyzed by autoradiography on a Cyclone Plus Storage Phosphor Scanner 111 
(PerkinElmer) and data analysis was performed using OptiQuant software (PerkinElmer). The reaction 112 
showing the chelation ratio closest to 50% was used to determine the amount of DTPA needed to chelate 113 
100% of the added activity and thus the effective specific activity. 114 
 115 
X-ray and Auger emission spectra  116 
The initial-vacancy distribution and the energy spectra of X-rays and Auger electrons following the 117 
decays of isolated 
135
La atoms were calculated according to the methodology presented by Lee et al. [16] 118 
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with 10
5
 Monte Carlo simulated decays. Both the condensed phase and isolated atom models were used 119 
for determining the cascade distributions.  120 
 121 
Dosimetry 122 
 123 
On a cellular scale, dosimetry was treated in two ways: first by use of MIRDCell, a formalism developed 124 
by MIRD (Medical Internal Radiation Dose) for calculation of cellular S-values [20,21]; and second by 125 
the COOLER code [22]. The S-value is defined as the absorbed dose in the target structure from a 126 
radioactive decay in the source structure, typically given in the unit Gy/(Bq·s) and denoted as S(Target←127 
Source). In this case, the target was taken to be the cell nucleus. Contributions to the nucleus (N) from the 128 
nucleus (N), S(N←N), from the cytoplasm (Cy), S(N←Cy), and from the cell surface (CS), S(N←CS), 129 
were separately determined. In this work, we performed MIRD-based calculations, totally within the 130 
MIRD framework by taking the individual electron branches (Table 2), evaluating them in MIRDCell, 131 
and then summing the doses over all emissions [20].  MIRDCell was also used to calculate the cellular 132 
dosimetry of 
177
Lu and 
90
Y. This gave the MIRD cellular S-values as proxies for the cellular dosimetry for 133 
all three isotopes (depending on the target size and source distribution). For the calculations we chose a 134 
cell radius of 7 µm and nucleus radius of 5 µm. This allowed comparison with the COOLER formalism 135 
(the COOLER V79 cell setting has radii of 7.1 and 5.2 µm, respectively). COOLER is a new cellular 136 
dosimetry approach that uses Monte-Carlo derived stopping powers (based on PARTRAC simulations 137 
[23]). This is in contrast to MIRDCell which uses Cole’s electron ranges to derive an electron stopping 138 
power [22,24]. The Monte-Carlo derived stopping powers generally result in altered dose distributions, 139 
especially for electrons with energies in the range of 5-35 keV, coinciding with the important Auger 140 
branches of the lanthanides. 141 
  142 
In order to predict how a heterogeneously targeted tumor of macroscopic dimensions would receive dose 143 
across many cell diameters, electron dose kernels were calculated in two different ways. First, by taking 144 
the full electron emission spectrum (including Augers, nuclear beta emissions, and conversion electrons 145 
[13,14,25]) and folding it with the range-versus-energy relationship from Cole. The dose-point kernel was 146 
calculated in MATLAB for 
135
La, 
177
Lu and 
90
Y. The calculation was performed using a step-size of 0.2 147 
µm. Second, the electron dose-point kernel of 
135
La was also calculated using the COOLER formalism.  148 
Results: 149 
Cyclotron Production of 
135
La from 
nat
Ba 150 
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When pressing the barium into the target holder, it was important to move quickly to limit the exposure of 151 
the barium to air. Within the minimal (~1 minute) pressing time, a white film was observed to form over 152 
the normally shiny barium. The pressed target appeared smooth, and likely had very limited surface area 153 
after pressing, as compared to the dendritic chunks. In most experiments, no discoloration or alteration of 154 
the target surface was observed after irradiation at a target current of 15 µA. Both aluminum (100 µm) 155 
and niobium (25 µm) were tested as front foil materials, and we did not observe any qualitative difference 156 
in target behavior between the two.  157 
 158 
The end-of-saturation bombardment (EOSB) yields for the nuclides (t1/2 > 3 h) produced during proton 159 
irradiation of 
nat
Ba at 15.8 MeV (after degradation in the aluminum cover foil) are given in Table 1.  160 
 161 
 
nuclide 
 
t1/2  
(h) 
 
EOSB  
(MBq/µA) 
135
La 18.9 429 
135m
Ba 28.8 4 
133
La 3.9 29 
* 
132
La 4.6 5 
 162 
Table 1: Thick target EOSB yields for proton irradiation of 
nat
Ba.  Only nuclides with t½ > 3 h are listed. *) 
132
La is produced 163 
both directly and via decay of the co-produced 
132m
La isomer. The number presented here reflects the amount of 
132
La 164 
produced in total after all 
132m
La has decayed to the ground state. Half-lives were obtained from  refs: [11,13,26]. 165 
Shorter irradiations produced a proportionately larger amount of the short-lived impurities. These short-166 
lived impurities will, at longer irradiation times, approach saturation and constitute a smaller proportion 167 
of the total radioactivity. Therefore the radionuclidic purity of 
135
La (with respect to the decay rate of the 168 
other lanthanum isotopes) increases with irradiation time as long as the 
135m
Ba impurity is chemically 169 
removed. 170 
 171 
Target dissolution and purification of 
135
La on Accell Plus CM resin 172 
Dissolution of the irradiated 
nat
Ba was always rapid (3-5 min) in the HCl solution. The trapping efficiency 173 
of 
135
La on the small column of CM resin was >99%. Several loading conditions were tested: with or 174 
without the 30 minute heating step, and both ammonium acetate and HEPES buffers were tested: each at 175 
pH 4 and 6.  It was observed that the 30-minute heating at 70 °C greatly improved trapping. When 176 
omitting this step loading efficiencies of only 50% were observed. Additionally, by re-acidifying and 177 
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heating any washed-through solution it was possible to retain all previously untrapped activity on a 178 
second column (further illustrating the importance of heating). When comparing the two buffers, 179 
ammonium acetate and HEPES, it was found that HEPES at pH = 6 resulted in higher trapping efficiency. 180 
The 0.1 M hydrochloric acid elution (1 mL) was >99% efficient at releasing the 
135
La.  181 
 182 
Chemical purity and molar activity measurements 183 
ICP-OES analysis revealed the concentration of metal contaminants in the final elution. Barium was still 184 
present at a concentration of 3.68 ± 0.09 µg/MBq. Cr, Mn and Fe were measured in concentrations of 185 
1.64 ± 1.05 ng/MBq, 1.19 ± 0.81 ng/MBq and 1.57 ± 0.33 ng/MBq, respectively. Using the final barium 186 
concentration, the separation factor was 138 ± 36.  In principle, the barium removal could also have been 187 
verified by the absence of coproduced 
135m
Ba, as this isotope is not formed by the decay of 
135
La. 188 
However, the sensitivity and specificity of the gamma spectroscopy was not sufficient to detect the 189 
remaining low level of barium.  190 
 191 
The molar activity of 
135
La determined by stable lanthanum assay on ICP-OES was over-optimistic for the 192 
expected labelling efficiency. This is because any other lanthanide, or similar hard metal ion impurity, 193 
could compete for labelling positions on vectors. Instead, the effective molar activity was assessed by 194 
thin-layer chromatography analysis of DTPA titrations. In all cases, a small amount (10-15%) of 
135
La 195 
remained at the origin of the TLC sheet no matter how large the excess of DTPA. This was believed to be 196 
due to formation of an inert lanthanum complex in the labeling solution, but the exact nature of the 197 
immobile 
135
La was not determined. Assuming 10% of the 
135
La was thermodynamically unavailable, the 198 
DTPA titrations showed an effective molar activity of 70.4 ± 20.0 GBq/µmol. 199 
 200 
X-ray and Auger emission spectra 201 
The initial-vacancy distribution for 
135
Ba following the electron capture (EC) and internal conversion (IC) 202 
processes was calculated, and as expected >99.9% of the initial vacancies created in atomic shells were 203 
due to EC. The resulting total K vacancy probability was 84.9% and the total L vacancy probability was 204 
11.9%. Internal conversion and electron capture processes in higher shells constituted the remaining 3.2% 205 
of vacancies. 206 
The calculated X-ray and Auger spectra following the decay of 
135
La in the condensed-phase 207 
approximation are shown in figure 2. The Auger-cascade simulations give only a small difference in the 208 
resulting Auger branching ratios between the condensed-phase (with continuous filling of the outermost 209 
vacancies) and isolated-atom approximations. The dose-point kernels derived from the two 210 
approximations were found to slightly differ from each other only in the first 100 nm [27]. For the 211 
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purpose of dosimetry and possible therapeutic use, the effect is negligible and the condensed phase 212 
spectra were used for dosimetry calculations. 213 
  214 
 215 
Figure 2 Histograms (bin-size 1 eV) showing the X-ray (red) and Auger (blue) kinetic energy spectra following the decay 216 
of 135La atoms in the condensed-phase approximation of BrIccEmis. These results are tabulated in Table 2. 217 
 218 
Yields per decay and mean energies of the main groups of Auger electrons are summarized in Table 2. 219 
The BrIccEmis derived spectrum is shown in Figure 2. Total energies released through X-rays and Auger 220 
electrons per decay, are 25.8 and 6.45 keV, respectively. There are on average 10.6 Auger electrons per 221 
decay (>97% of total) that have energies less than 4 keV. The maximum range of these very low-energy 222 
electrons is <0.5 µm in water [28]. 223 
  224 
 225 
 226 
 227 
 Yield 
/decay 
Mean energy  
(keV) 
Auger KLL 0.055 26.3 
Auger KLX 0.025 31.0 
Auger KXY 0.003 35.6 
CK LLX 0.131 0.333 
Auger LMM 0.580 3.53 
Auger LMX 0.185 4.33 
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Auger LXY 0.014 5.15 
CK MMX 0.634 0.104 
Auger MXY 1.59 0.538 
Super-CK NNN 0.277 0.007 
CK NNX 1.33 0.049 
Auger NXY 4.27 0.039 
CK OOX 1.78 0.009 
Auger OXY 0.023 0.030 
Total 10.9 0.592 
Table 2: Auger average spectrum following 135La decay, the standard deviation in the total number of electrons ejected per 228 
decay is 3.2 e
-
/(Bq s). 229 
 230 
X-ray Yield /decay Mean energy  
(keV) 
Kα1 0.404 32.3 
Kα2 0.220 31.9 
Kβ1 0.075 36.5 
Kβ2 0.024 37.4 
Kβ3 0.039 36.4 
Kβ4 <0.001 37.5 
Kβ5 <0.001 36.8 
KO* 0.003 37.6 
L 0.098 4.71 
M 0.007 0.711 
N <0.001 0.123 
Total 0.871 29.6 
*All other K X-rays.  
Table 3. X-ray average spectrum following 135La decay.  231 
Dosimetry 232 
The S-factors derived in this work are given in Table 4. From these results, it is clear that the calculated 233 
cellular S-factors based on the BrIccEmis derived Auger spectrum of 
135
La are different from those 234 
obtained when using the spectrum from NuDat 2 [14]. The BrIccEmis derived spectrum yields higher 235 
S(N←N) but lower S(N←Cy) and S(N←CS). These changes follow from the fact that the BrIccEmis 236 
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derived spectrum has a higher overall yield of low-energy Auger electrons and a slightly lower overall 237 
yield of the higher-energy K-shell Auger electrons. The low-energy emissions are more dose-intensive 238 
when inside the cell nucleus, while the higher energy emissions are more effective at supplying dose to 239 
the nucleus when they are localized in cytoplasm and on cell surfaces. This is because low energy 240 
emissions have a lower probability of reaching the nucleus from these compartments. 241 
The S-factors calculated using the COOLER formalism show increased dose for the compartments (N←242 
Cy) and (N←CS), 38% and 89% respectively while (N←N) showed a 5% decrease, using this newly 243 
calculated spectrum as compared to the MIRDCell formalism.  244 
 245 
Comparing the dose delivered from 
135
La to that of 
177
Lu and 
90
Y, it is seen that for (N←N), 
135
La delivers 246 
a higher dose to the nucleus than 
177
Lu and 
90
Y. However, this is not the case when the decay occurs in 247 
the cytoplasm or on the cell surface. Comparing the new 
135
La spectrum to 
177
Lu, the dose ratio is 4 and 248 
5.5 for the compartments (N←Cy) and (N←CS) respectively. This means that four disintegrations of 249 
135
La are needed to deliver absorbed dose, equal to that associated with a single disintegration of 
177
Lu in 250 
the cytoplasm. For 
90
Y the dose ratios are 1.3 and 2, respectively. However, the number of interest when 251 
assessing the potential of a therapeutic isotope is not the dose delivered per disintegration, but the target-252 
to-normal ratio i.e., the dose delivered to the target divided by the dose delivered to normal tissue.  253 
 254 
 MIRDCell COOLER 
S-value BrIccEmis NuDat 2 spectrum BrIccEmis NuDat 2 spectrum 
S(N←N) 1.29E-03 9.51E-04 1.23E-03 9.45E-04 
S(N←Cy) 6.81E-05 7.06E-05 9.39E-05 1.02E-04 
S(N←CS) 3.09E-05 3.46E-05 5.84E-05 6.41E-05 
Table 4: Comparison of the cellular S-factors [Gy/(Bq*s)]  for 135La calculated in MIRDCell (left) and COOLER (right) using the 255 
new Monte Carlo based Auger spectrum and, as reference, the input spectrum available in the NuDat 2 database [14]. 256 
 257 
 COOLER
 
MIRDCell 
S-value 
135
La 
BrIccEmis 
177
Lu 
MIRD 
90
Y 
MIRD 
S(N←N) 1.23E-03 1.05E-03 2.54E-04 
S(N←Cy) 9.39E-05 2.78E-04 9.09E-05 
S(N←CS) 5.84E-05 1.72E-04 6.15E-05 
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Table 5 A comparison of the cellular S-factor [Gy/(Bq*s)]  of 
135
La calculated in COOLER, to those of the traditional β-emitting 258 
therapeutic radionuclides 
177
Lu and 
90
Y calculated in MIRDCell.  259 
The relative merit of 
135
La for single cell or small cell-cluster therapy as compared with the “standard” 260 
therapeutic nuclides 
177
Lu and 
90
Y is obvious in Figure 3. It shows the fraction of emitted electron energy 261 
absorbed within spheres of ever growing radii. Only 
135
La is treated using both the COOLER and the Cole 262 
stopping power approach, seeing that the COOLER formalism, at present, is not capable of handling the 263 
high electron energies associated with 
177
Lu and 
90
Y decay (currently limited to 50 keV). 264 
 265 
Figure 3 Fraction of electron kinetic energy absorbed within spheres as function of sphere radius. The energy deposition is 266 
calculated using the Cole stopping power as stated and used in the introduction of MIRD Cellular S-values [24], with 267 
exception of the “La-135 Cooler” curve (red) which was calculated using the COOLER code. The input for the continuous 268 
beta spectra are taken from RADAR[29] (90Y and 177Lu), the conversion- and Auger electrons from NuDat 2, except for 269 
135La, where the new, calculated Auger spectrum is used. Photons, including bremsstrahlung, are omitted. 270 
Figure 3 however, hides the full impact of the Auger emissions from 
135
La. In very small spheres (radius 271 
less than the diameter of cell nucleus) surrounding a 
135
La decay, the local dose is very high. This can be 272 
seen in Figure 4 which shows the dose-point kernel for 
135
La as calculated with the new spectrum and 273 
both the COOLER and the Cole stopping power formalisms. 274 
 275 
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 276 
Figure 4: Dose-point kernels for 135La Auger electron emissions (X-rays are not included) for both the COOLER and 277 
Cole/MIRD methodologies. In both cases, the calculations were performed using the Auger spectrum obtained from the 278 
BrIccEmis simulation.  279 
 280 
Discussion: 281 
 282 
The Auger emitter 
135
La is a potential radionuclide for targeted internal therapy. From the view of 283 
production and purification, the route via proton irradiation of 
nat
Ba is straightforward. Clearly, the rate of 284 
production and the radionuclidic purity of 
135
La could be improved by irradiating enriched 
135
Ba, but 285 
further target development would be required to allow either irradiation of a barium oxide or salt, or to 286 
accommodate reduction of recycled 
135
Ba
2+
 after the separation procedure. While the overall separation 287 
factor achieved in this report is not impressive ~10
2
, the fact that high labeling effective specific activity 288 
is obtained demonstrates that rigorous separation is not critical. Here, the measured effective specific 289 
activity is a positive indicator for the expected labeling yield. The value measured by DTPA titration of 290 
(70.4 ± 20.0 GBq/µmol) corresponds well with what would be expected from the ICP analysis. If, for 291 
some applications, higher effective specific activities are required, an additional step to ensure the 292 
removal of iron and manganese could be employed [30]. It should be noted that the exact impurity profile 293 
of competing metals will depend on the initial purity of the barium stock used. 294 
  295 
When turning to the emissions of 
135
La, we show the results of calculations using the BrIccEmis code 296 
from Lee et al. [16]. Importantly this method accounts for multiple vacancies during the cascade. Notably, 297 
if the atomic transition energies are approximated using neutral binding energies, and thereby neglecting 298 
the effect of multiple vacancies, this could give rise to multiple energies for a given atomic transition due 299 
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to the stochastic nature of the Auger cascade. Falzone & Lee et al. showed that MIRD RADTABS 300 
disagree with the experimental L-Auger spectrum of 
131
Cs and demonstrated that the theoretical L-Auger 301 
energy spectrum of 
131
Cs agreed with experiment only when the effect of multiple vacancies was taken 302 
into account [27,31] .  303 
 304 
In the present case, the use of the newly calculated Auger spectrum does not result in dramatically 305 
different cellular dosimetry. However, the exact shape of the spectrum at low energies can become 306 
extremely important as cellular and subcellular targeting becomes more exact. This is because the 307 
expected biological effect of Auger emitters may not solely rely on the dose, but also on the RBE of the 308 
low energy electrons. An important part of the Auger emitter concept is the expectation of an RBE larger 309 
than that of conventional gamma or beta irradiation. RBE is the measure used to compare different types 310 
of radiation gray-to-gray, assessing the biological damage done. A common measure for the biological 311 
damage is DNA double-strand breaks, which are potentially more likely to occur in close proximity to the 312 
decay site of an Auger emitter. For higher energy electron and beta emissions (> 20 keV), creating a 313 
double-strand break with a single pass of an electron is highly unlikely because the mean path length 314 
between subsequent ionization events is much larger than the distance between the DNA strands. 315 
Therefore multiple electrons stemming from multiple decays have to pass through or get in close 316 
proximity to the same area of the DNA strand to create a double-strand break. With an Auger emitter this 317 
is not the case. Due to the multiple electrons emitted in a single decay (10.9 ± 3.2/decay for 
135
La) only a 318 
single decay is potentially enough to cause the double-strand break if the decay occurs close to the DNA. 319 
Additionally, the decaying atom would find itself highly ionized due to multiple emissions of Auger 320 
electrons and thus could be highly oxidizing to the immediate environment. From a physical perspective, 321 
these two factors combined should result in an RBE much higher than 1, meaning more effective therapy 322 
per gray deposited. A recent paper has described how the cell surface is more radiosensitive than assumed 323 
in MIRD [32]. The calculations presented in this paper only consider dose to the nucleus, however 324 
incorporating the cell surface as a sensitive target would make the case for 
135
La even stronger, seeing that 325 
this would decrease the importance of internalization. 326 
 327 
It is also important to understand that the low amount energy emitted per decay of 
135
La does not preclude 328 
effective therapy. For therapeutic benefit, the relevant metric is not the absolute dose-per-decay but the 329 
ratio of the dose absorbed by the target to the dose absorbed by the surrounding healthy tissue. 330 
Commonly, the limiting factor is the absorbed dose in healthy tissue immediately surrounding the 331 
targeted cell, or the absorbed dose in clearance organs. When considering the absorbed dose to the 332 
immediate surroundings, the benefit of using 
135
La is clear from Figure 3 and Figure 4, where the absence 333 
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of higher energy beta electrons and the limited Auger-electron range of 
135
La results in dramatically 334 
reduced dose beyond one cell diameter. As is the case with any Auger emitter, there are clear benefits of 335 
using 
135
La when the target being treated is very small.  336 
 337 
Conclusion: 338 
A method has been developed allowing the production of clinically relevant amounts of 
135
La using 339 
medical cyclotrons. The developed purification method is fast, robust and essentially loss-less. 
135
La has a 340 
well-suited half-life for therapy. The calculated cellular dosimetry shows that the emissions from 
135
La 341 
lead to cellular S-values that are promising for internal radionuclide therapy of very small targets, with 342 
dosimetry superior to 
177
Lu and 
90
Y at single-cell dimension. This along with the mounting evidence of 343 
Auger emitters having an RBE > 1 strongly motivates further research in application of Auger emitters in 344 
treatment of single cancerous cells and micro-metastasis. 345 
 346 
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